Comparative effects of telmisartan and eprosartan on insulin sensitivity in the treatment of overweight hypertensive patients

R. Fogari, A. Zoppi, I. Ferrari, A. Mugellini, P. Preti, P. Lazzari, G. Derosa

Research output: Contribution to journalArticle

Abstract

The aim of this study was to compare the effect of telmisartan and eprosartan on insulin sensitivity in overweight hypertensive patients. Fifty overweight (BMI≥25 and 2) outpatients, aged 41-65 years, with mild to moderate hypertension [systolic blood pressure (SBP) >140 and diastolic blood pressure (DBP) ≥90 and ≤110mmHg], after a 4-week placebo period, were randomized to receive telmisartan 80mg or eprosartan 600mg for 8 weeks. Following another 4-week placebo period, patients were crossed to the alternative regimen for further 8 weeks. At the end of each placebo and active treatment period, blood pressure (BP), insulin sensitivity (by euglycemic hyperinsulinemic clamp), fasting plasma glucose (FPG), insulin (FPI), total cholesterol (TC), LDL-C, HDL-C, and triglycerides (Tg) were evaluated. Insulin sensitivity was expressed as the amount of glucose infused during the last 30min (glucose infusion rate, GIR) in μmol/min/kg. Both telmisartan and eprosartan significantly reduced SBP/DBP values (by a mean of 19.4/13.3mmHg and 17.9/12.1mmHg respectively, all p

Original languageEnglish
Pages (from-to)893-898
Number of pages6
JournalHormone and Metabolic Research
Volume41
Issue number12
DOIs
Publication statusPublished - 2009

Keywords

  • AT 1 blockers
  • Body weight
  • Hyperinsulinemic clamp
  • Hypertension
  • Insulin resistance
  • Sartans

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Endocrinology
  • Biochemistry, medical
  • Endocrinology, Diabetes and Metabolism

Fingerprint Dive into the research topics of 'Comparative effects of telmisartan and eprosartan on insulin sensitivity in the treatment of overweight hypertensive patients'. Together they form a unique fingerprint.

  • Cite this